GlaxoSmithKline S.A.E

BIOC

EGS38171C012

Pharmaceuticals

End-of-day quote Egyptian Exchange Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
30.13 ^EGP	-0.20%		-3.06%	-15.25%

04/03	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2021

May 30, 2022 at 02:33 pm IST

GlaxoSmithKline S.A.E reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EGP 1,812.04 million compared to EGP 1,992.83 million a year ago. Net income was EGP 154.64 million compared to EGP 28.13 million a year ago. Basic earnings per share from continuing operations was EGP 1.85 compared to EGP 0.34 a year ago.

Latest news about GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023	04/03	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/11	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2023	31/23/31	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30	CI
GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
GlaxoSmithKline S.A.E Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	12/21/12	CI
Glaxosmithkline S.A.E Reports Standalone and Consolidated Financial Results for the Quarter Ended March 31, 2021	16/21/16	CI
Glaxosmithkline S.A.E Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2020	01/21/01	CI
Hikma Pharmaceuticals PLC cancelled the acquisition of GlaxoSmithKline S.A.E.	11/21/11	CI
Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline Shares	01/21/01	CI
Hikma Pharmaceuticals PLC entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E from Glaxo Group Limited.	26/21/26	CI
GlaxoSmithKline S.A.E Reports Audited Standalone Earnings Results for the Year Ended December 31, 2019	01/20/01	CI
GSK Egypt to Launch 2 Production Lines with EGP 100 million Investments	21/19/21	CI
Glaxo Smith Kline Announces Consolidated Earning Results for the Nine Months Ended September 30, 2018	22/19/22	CI
GlaxoSmithKline S.A.E Announces Consolidated and Standalone Earnings Results for the First Quarter Ended March 31, 2018	27/18/27	CI
GlaxoSmithKline S.A.E Announces Consolidated and Standalone Earnings Results for the Six Months Ended June 30, 2018	27/18/27	CI
GlaxoSmithKline plc Declares Cash Dividends, Payable on October 18, 2018	14/18/14	CI
Glaxo Smith Kline Reports Audited Consolidated and Standalone Earnings Results for the Year Ended December 31, 2017	30/18/30	CI
Glaxo Smith Kline Announces Consolidated and Standalone Earning Results for the Nine Months Ended September 30, 2017	03/18/03	CI
Glaxo Smith Kline Announces Cash Dividend, Payable on December 28, 2017	17/17/17	CI
Glaxo Smith Kline Reports Consolidated Earnings Results for the Six Months Ended June 30, 2017	14/17/14	CI
Glaxo Smith Kline Reports Standalone Earnings Results for the Six Months Ended June 30, 2017	13/17/13	CI
Glaxo Smith Kline Reports Standalone and Consolidated Earnings Results for the Quarter Ended March 31, 2017	14/17/14	CI

Chart GlaxoSmithKline S.A.E

Duration

Period

More charts

Company Profile

GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GLAXOSMITHKLINE S.A.E	-15.25%	53.09M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals